{{Drugbox
| verifiedrevid = 461936291
| IUPAC_name = 3-(10,11-dihydro-5''H''-dibenzo[''b,f'']azepin-5-yl)-''N'',''N''-dimethylpropan-1-amine
| image = Imipramine.svg
| width = 175px
| image2 = Imipramine-3D-balls.png
| width2 = 175px
<!--Clinical data-->
| tradename = Tofranil, Tofranil-PM, others
| synonyms = Melipramine; G-22355
| Drugs.com = {{drugs.com|monograph|imipramine-hydrochloride}}
| MedlinePlus = a682389
| pregnancy_AU = C
| pregnancy_US = N
| legal_AU = S4
| legal_US = Rx-only
| legal_CA = Rx-only
| legal_UK = POM
| routes_of_administration = [[Oral administration|Oral]], [[intramuscular injection]]
<!--Pharmacokinetic data-->
| bioavailability = 94–96%<ref name = Pharm>{{cite journal |title=Bioavailability of imipramine tablets relative to a stable isotope-labelled internal standard: increasing the power of bioavailability tests|journal=Journal of Pharmacokinetics and Biopharmaceutics|date=June 1979|volume=7|issue=3|pages=233–248|pmid=480146|doi=10.1007/bf01060015|author=Heck HA, Buttrill SE Jr, Flynn NW, Dyer RL, Anbar M, Cairns T, Dighe S, Cabana BE}}</ref>
| protein_bound = 86%<ref name = TOLERADE />
| metabolism = [[Hepatic]] ([[CYP1A2]], [[CYP2C19]], [[CYP2D6]])<ref name="TOLERADE">{{cite web|title=PRODUCT INFORMATION TOLERADE® (imipramine hydrochloride)|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07434-3|work=TGA eBusiness Services|publisher=PMIP Pty Ltd|accessdate=16 October 2013|date=4 June 2013}}</ref>
| metabolites = [[Desipramine]] (main active metabolite)<ref name="TOLERADE" />
| elimination_half-life = 20 hours<ref name = TOLERADE />
| excretion = [[Renal]] (80%), [[feces|fecal]] (20%) (mostly as inactive metabolites)<ref name = TOLERADE />
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-49-7
| ATC_prefix = N06
| ATC_suffix = AA02
| PubChem = 3696
| IUPHAR_ligand = 357
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00458
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3568
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = OGG85SX4E4
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08070
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 47499
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 11
<!--Chemical data-->
| C=19 | H=24 | N=2
| molecular_weight = 280.407 g/mol
| SMILES = c1cc3c(cc1)CCc2c(cccc2)N3CCCN(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BCGWQEUPMDMJNV-UHFFFAOYSA-N
}}

'''Imipramine''', sold under the brand name '''Tofranil''' among others, is a [[tricyclic antidepressant]] (TCA). It is mainly used in the treatment of [[major depressive disorder|major depression]] and [[enuresis]] (inability to control [[urination]]).

==Medical uses==
Imipramine is used in the treatment of depression, such as depression associated with agitation or anxiety. It is similar in efficacy to the antidepressant drug [[moclobemide]].<ref name="pmid8557884">{{cite journal |title=Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies |journal=Journal of Affective Disorders |volume=35 |issue=1–2 |pages=21–30 |date=October 1995 |pmid=8557884 |doi=10.1016/0165-0327(95)00034-K |author1=Delini-Stula |first1=A |last2=Mikkelsen |first2=H |last3=Angst |first3=J }}</ref> It has also been used to treat [[nocturnal enuresis]] because of its ability to shorten the time of [[delta wave]] stage sleep, where wetting occurs. In veterinary medicine, imipramine is used with [[xylazine]] to induce pharmacologic ejaculation in stallions.

==Side effects==
Those listed in ''italics'' below denote common side effects.<ref>{{Cite book|editor=Skidmore-Roth, L.|year=2010|title=Mosby's Nursing Drug Reference|edition=23rd |location=St. Louis, MO|publisher= Mosby Elsevier}}</ref>

* Central nervous system: ''dizziness'', ''drowsiness'', confusion, seizures, headache, anxiety, tremors, stimulation, weakness, insomnia, nightmares, [[extrapyramidal symptoms]] in geriatric patients, increased psychiatric symptoms, [[paresthesia]]
* Cardiovascular: ''[[orthostatic hypotension]]'', ''ECG changes'', ''tachycardia'', hypertension, palpitations, dysrhythmias
* Eyes, ears, nose and throat: blurred vision, tinnitus, [[mydriasis]]
* Gastrointestinal: ''dry mouth'', nausea, vomiting, [[paralytic ileus]], increased appetite, cramps, epigastric distress, jaundice, hepatitis, stomatitis, constipation, taste change
* Genitourinary: ''urinary retention''
* Hematological: [[agranulocytosis]], [[thrombocytopenia]], [[eosinophilia]], [[leukopenia]]
* Skin: rash, [[urticaria]], [[diaphoresis]], [[pruritus]], photosensitivity

==Overdose==
{{Main|Tricyclic antidepressant overdose}}

==Pharmacology==

===Pharmacodynamics===
{{See also|Pharmacology of antidepressants|Tricyclic antidepressant#Binding profiles}}
{| class="wikitable floatleft" style="font-size:small;"
|+ Imipramine (and metabolite)<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=imipramine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! {{abbr|IMI|Imipramine}} !! {{abbrlink|DSI|Desipramine}} !! Species !! Ref
|-
| '''{{abbrlink|SERT|Serotonin transporter}}''' || '''1.3–1.4''' || '''17.6–163''' || '''Human''' || <ref name="pmid9537821">{{cite journal | vauthors = Tatsumi M, Groshan K, Blakely RD, Richelson E | title = Pharmacological profile of antidepressants and related compounds at human monoamine transporters | journal = Eur. J. Pharmacol. | volume = 340 | issue = 2-3 | pages = 249–58 | year = 1997 | pmid = 9537821 | doi = | url = }}</ref><ref name="pmid9400006">{{cite journal | vauthors = Owens MJ, Morgan WN, Plott SJ, Nemeroff CB | title = Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites | journal = J. Pharmacol. Exp. Ther. | volume = 283 | issue = 3 | pages = 1305–22 | year = 1997 | pmid = 9400006 | doi = | url = }}</ref>
|-
| '''{{abbrlink|NET|Norepinephrine transporter}}''' || '''20–37''' || '''0.63–3.5''' || '''Human''' || <ref name="pmid9537821" /><ref name="pmid9400006" />
|-
| {{abbrlink|DAT|Dopamine transporter}} || 8,500 || 3,190 || Human || <ref name="pmid9537821" />
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || ≥5,800 || ≥6,400 || Human || <ref name="pmid7855217" /><ref name="pmid9686407" /><ref name="pmid3816971">{{cite journal | vauthors = Wander TJ, Nelson A, Okazaki H, Richelson E | title = Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro | journal = Eur. J. Pharmacol. | volume = 132 | issue = 2-3 | pages = 115–21 | year = 1986 | pmid = 3816971 | doi = | url = }}</ref>
|-
| '''[[5-HT2A receptor|5-HT<sub>2A</sub>]]''' || '''80–150''' || '''115–350''' || '''Human''' || <ref name="pmid7855217" /><ref name="pmid3816971" />
|-
| '''[[5-HT2C receptor|5-HT<sub>2C</sub>]]''' || '''120''' || '''244–748''' || '''Human/rat''' || <ref name="pmid16712488">{{cite journal | vauthors = Roth BL, Kroeze WK | title = Screening the receptorome yields validated molecular targets for drug discovery | journal = Curr. Pharm. Des. | volume = 12 | issue = 14 | pages = 1785–95 | year = 2006 | pmid = 16712488 | doi = | url = }}</ref><ref name="pmid8876023">{{cite journal | vauthors = Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J | title = Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor | journal = Psychopharmacology | volume = 126 | issue = 3 | pages = 234–40 | year = 1996 | pmid = 8876023 | doi = | url = }}</ref><ref name="pmid9686407">{{cite journal | vauthors = Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS | title = Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications | journal = NIDA Res. Monogr. | volume = 178 | issue = | pages = 440–66 | year = 1998 | pmid = 9686407 | doi = | url = }}</ref>
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || 970–3,651 || ≥2,500 || Rodent || <ref name="pmid9686407" /><ref name="pmid2533080">{{cite journal | vauthors = Schmidt AW, Hurt SD, Peroutka SJ | title = '[3H]quipazine' degradation products label 5-HT uptake sites | journal = Eur. J. Pharmacol. | volume = 171 | issue = 1 | pages = 141–3 | year = 1989 | pmid = 2533080 | doi = | url = }}</ref>
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 190–209  || {{abbr|ND|No data}} || Rat || <ref name="pmid7680751">{{cite journal | vauthors = Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR | title = Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs | journal = Mol. Pharmacol. | volume = 43 | issue = 3 | pages = 320–7 | year = 1993 | pmid = 7680751 | doi = | url = }}</ref>
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || >1,000 || >1,000 || Rat || <ref name="pmid8394362">{{cite journal | vauthors = Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR | title = Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype | journal = J. Biol. Chem. | volume = 268 | issue = 24 | pages = 18200–4 | year = 1993 | pmid = 8394362 | doi = | url = }}</ref>
|-
| '''[[Alpha-1 adrenergic receptor|α<sub>1</sub>]]''' || '''32''' || '''23–130''' || '''Human''' || <ref name="pmid7855217" /><ref name="pmid6086881" /><ref name="pmid9400006" />
|-
| [[Alpha-2 adrenergic receptor|α<sub>2</sub>]] || 3,100 || ≥1,379 || Human || <ref name="pmid7855217" /><ref name="pmid6086881" /><ref name="pmid9400006" />
|-
| [[Beta-adrenergic receptor|β]] || >10,000 || ≥1,700 || Rat || <ref name="pmid2530094">{{cite journal | vauthors = Andersen PH | title = The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action | journal = Eur. J. Pharmacol. | volume = 166 | issue = 3 | pages = 493–504 | year = 1989 | pmid = 2530094 | doi = | url = }}</ref><ref name="pmid3790168">{{cite journal | vauthors = Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB | title = Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative | journal = Biochem. Pharmacol. | volume = 35 | issue = 24 | pages = 4493–7 | year = 1986 | pmid = 3790168 | doi = | url = }}</ref><ref name="pmid10379421">{{cite journal | vauthors = Sánchez C, Hyttel J | title = Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding | journal = Cell. Mol. Neurobiol. | volume = 19 | issue = 4 | pages = 467–89 | year = 1999 | pmid = 10379421 | doi = | url = }}</ref>
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || >10,000 || 5,460 || Human || <ref name="pmid9686407"/><ref name="pmid17850785">{{cite journal | vauthors = Deupree JD, Montgomery MD, Bylund DB | title = Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram | journal = Eur. J. Pharmacol. | volume = 576 | issue = 1-3 | pages = 55–60 | year = 2007 | pmid = 17850785 | pmc = 2231336 | doi = 10.1016/j.ejphar.2007.08.017 | url = }}</ref>
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 620–726 || 3,400 || Human || <ref name="pmid17850785" /><ref name="pmid9686407" /><ref name="pmid6086881" />
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || 387 || {{abbr|ND|No data}} || Human || <ref name="pmid9686407" />
|-
| '''[[Histamine H1 receptor|H<sub>1</sub>]]''' || '''7.6–37''' || '''60–110''' || '''Human''' || <ref name="pmid7855217">{{cite journal | vauthors = Cusack B, Nelson A, Richelson E | title = Binding of antidepressants to human brain receptors: focus on newer generation compounds | journal = Psychopharmacology | volume = 114 | issue = 4 | pages = 559–65 | year = 1994 | pmid = 7855217 | doi = | url = }}</ref><ref name="pmid6086881">{{cite journal | vauthors = Richelson E, Nelson A | title = Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro | journal = J. Pharmacol. Exp. Ther. | volume = 230 | issue = 1 | pages = 94–102 | year = 1984 | pmid = 6086881 | doi = | url = }}</ref><ref name="pmid22033803">{{cite journal | vauthors = Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R | title = Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 385 | issue = 2 | pages = 145–70 | year = 2012 | pmid = 22033803 | doi = 10.1007/s00210-011-0704-0 | url = }}</ref>
|-
| [[Histamine H2 receptor|H<sub>2</sub>]] || 550 || 1,550 || Human || <ref name="pmid22033803" />
|-
| [[Histamine H3 receptor|H<sub>3</sub>]] || >100,000 || >100,000 || Human || <ref name="pmid22033803" />
|-
| [[Histamine H4 receptor|H<sub>4</sub>]] || 24,000 || 9,550 || Human || <ref name="pmid22033803" />
|-
| '''{{abbrlink|mACh|Muscarinic acetylcholine receptor}}''' || '''46''' || '''66–198''' || '''Human''' || <ref name="pmid7855217" /><ref name="pmid6086881" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]]''' || '''42''' || '''110''' || '''Human''' || <ref name="pmid8100134">{{cite journal |vauthors=Stanton T, Bolden-Watson C, Cusack B, Richelson E |title=Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics |journal=Biochem. Pharmacol. |volume=45 |issue=11 |pages=2352–4 |year=1993 |pmid=8100134 |doi= |url=}}</ref>
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]]''' || '''88''' || '''540''' || '''Human''' || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]]''' || '''60''' || '''210''' || '''Human''' || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]]''' || '''112''' || '''160''' || '''Human''' || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]]''' || '''83''' || '''143''' || '''Human''' || <ref name="pmid8100134" />
|-
| [[Alpha-3 beta-4 nicotinic receptor|α3β4]] || 410–970 || {{abbr|ND|No data}} || Human || <ref name="pmid20117161">{{cite journal | vauthors = Arias HR, Targowska-Duda KM, Feuerbach D, Sullivan CJ, Maciejewski R, Jozwiak K | title = Different interaction between tricyclic antidepressants and mecamylamine with the human alpha3beta4 nicotinic acetylcholine receptor ion channel | journal = Neurochem. Int. | volume = 56 | issue = 4 | pages = 642–9 | year = 2010 | pmid = 20117161 | doi = 10.1016/j.neuint.2010.01.011 | url = }}</ref>
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]] || 332–520 || 1,990–4,000 || Rodent || <ref name="pmid2877462">{{cite journal | vauthors = Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JF | title = 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 83 | issue = 22 | pages = 8784–8 | year = 1986 | pmid = 2877462 | pmc = 387016 | doi = | url = }}</ref><ref name="pmid20373470">{{cite journal | vauthors = Hindmarch I, Hashimoto K | title = Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered | journal = Hum Psychopharmacol | volume = 25 | issue = 3 | pages = 193–200 | year = 2010 | pmid = 20373470 | doi = 10.1002/hup.1106 | url = }}</ref><ref name="pmid21911285">{{cite journal | vauthors = Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR | title = Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo | journal = Eur Neuropsychopharmacol | volume = 22 | issue = 4 | pages = 308–17 | year = 2012 | pmid = 21911285 | doi = 10.1016/j.euroneuro.2011.08.002 | url = }}</ref>
|-
| [[Sigma-2 receptor|σ<sub>2</sub>]] || 327–2,100 || ≥1,611 || Rat || <ref name="PDSP" /><ref name="pmid20373470" /><ref name="pmid21911285" />
|-
| {{abbrlink|hERG|human Ether-à-go-go-Related Gene}} || 3,400 || {{abbr|ND|No data}} || Human || <ref name="pmid10510461">{{cite journal | vauthors = Teschemacher AG, Seward EP, Hancox JC, Witchel HJ | title = Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline | journal = Br. J. Pharmacol. | volume = 128 | issue = 2 | pages = 479–85 | year = 1999 | pmid = 10510461 | pmc = 1571643 | doi = 10.1038/sj.bjp.0702800 | url = }}</ref>
|- class="sortbottom"
| colspan="5" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

Imipramine affects numerous [[neurotransmitter system]]s known to be involved in the etiology of depression, anxiety, [[attention-deficit hyperactivity disorder]] (ADHD), enuresis and numerous other mental and physical conditions. Imipramine is similar in structure to some muscle relaxants, and has a significant analgesic effect and, thus, is very useful in some pain conditions.

The mechanisms of imipramine's actions include, but are not limited to, effects on:

* [[Serotonin]]: very strong reuptake inhibition.
* [[Norepinephrine]]: strong reuptake inhibition. Desipramine has more affinity to [[norepinephrine transporter]] than imipramine.
* [[Dopamine]]: imipramine blocks [[D2 receptor|D<sub>2</sub> receptor]]s.<ref>{{Cite journal|last=Smiałowski|first=A.|date=1991-05-01|title=Dopamine D2 receptor blocking effect of imipramine in the rat hippocampus|journal=Pharmacology, Biochemistry, and Behavior|volume=39|issue=1|pages=105–108|issn=0091-3057|pmid=1924491|doi=10.1016/0091-3057(91)90404-p}}</ref> Imipramine, and its metabolite desipramine, have no appreciable affinity for the [[dopamine transporter]] (K<sub>i</sub> = 8,500 and >10,000&nbsp;nM, respectively).<ref>{{Cite journal|last=Schulze|first=David R.|last2=Carroll|first2=F. Ivy|last3=McMahon|first3=Lance R.|date=2012-08-01|title=Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys|journal=Psychopharmacology|volume=222|issue=3|pages=425–438|doi=10.1007/s00213-012-2661-9|issn=0033-3158|pmc=3620032|pmid=22374253}}</ref> 
* [[Acetylcholine]]: imipramine is an [[anticholinergic]], specifically an antagonist of the [[muscarinic acetylcholine receptor]]s. Thus, it is prescribed with caution to the elderly and with extreme caution to those with psychosis, as the general brain activity enhancement in combination with the "dementing" effects of anticholinergics increases the potential of imipramine to cause hallucinations, confusion and delirium in this population.
* [[Epinephrine]]: imipramine antagonizes [[adrenergic receptor]]s, thus sometimes causing [[orthostatic hypotension]].
* [[Sigma receptor]]: activity on sigma receptors is present, but it is very weak (K<sub>i</sub> = 520&nbsp;nM) and it is about half that of amitriptyline (K<sub>i</sub> = 300&nbsp;nM).{{Citation needed|date=June 2016}}
* [[Histamine]]: imipramine is an antagonist of the histamine [[H1 receptor|H<sub>1</sub> receptor]]s.
* [[BDNF]]: BDNF is implicated in neurogenesis in the hippocampus, and studies suggest that depressed patients have decreased levels of BDNF and reduced hippocampal neurogenesis. It is not clear how neurogenesis restores mood, as ablation of hippocampal neurogenesis in murine models do not show anxiety related or depression related behaviours. Chronic imipramine administration results in increased histone acetylation (which is associated with transcriptional activation and decondensed chromatin) at the hippocampal BDNF promotor, and also reduced expression of hippocampal [[Histone deacetylase 5|HDAC5]].<ref>{{cite journal| title = Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action| journal = Nature Neuroscience| volume = 9| issue = 4| pages = 519–25| date=April 2006| pmid = 16501568| doi = 10.1038/nn1659| author1 = Tsankova| first1 = N. M.| last2 = Berton| first2 = O| last3 = Renthal| first3 = W| last4 = Kumar| first4 = A| last5 = Neve| first5 = R. L.| last6 = Nestler| first6 = E. J.}}</ref><ref>{{cite journal| title = The molecular neurobiology of depression| journal = Nature| volume = 455| issue = 7215| pages = 894–902| date=October 2008| pmid = 18923511| doi = 10.1038/nature07455| pmc = 2721780| bibcode=2008Natur.455..894K| author1 = Krishnan| first1 = V| last2 = Nestler| first2 = E. J.}}</ref>

===Pharmacokinetics===
Within the body, imipramine is converted into [[desipramine]] (desmethylimipramine) as a [[metabolite]].

==Chemistry==
Imipramine is a [[tricyclic compound]], specifically a [[dibenzazepine]], and possesses three [[ring (chemistry)|ring]]s fused together with a [[side chain]] attached in its [[chemical structure]].<ref name="Ritsner2013">{{cite book|author=Michael S Ritsner|title=Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies|url=https://books.google.com/books?id=jy-LMZU7338C&pg=PA270|date=15 February 2013|publisher=Springer Science & Business Media|isbn=978-94-007-5805-6|pages=270–271}}</ref> Other dibenzazepine TCAs include [[desipramine]] (''N''-desmethylimipramine), [[clomipramine]] (3-chloroimipramine), [[trimipramine]] (2'-methylimipramine or β-methylimipramine), and [[lofepramine]] (''N''-(4-chlorobenzoylmethyl)desipramine).<ref name="Ritsner2013" /><ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA580|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=580–}}</ref> Imipramine is a [[tertiary amine]] TCA, with its [[side chain]]-[[demethylation|demethylated]] metabolite desipramine being a [[secondary amine]].<ref name="CutlerSramek1994">{{cite book|author1=Neal R. Cutler|author2=John J. Sramek|author3=Prem K. Narang|title=Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology|url=https://books.google.com/books?id=ncRXa8Dq88QC&pg=PA160|date=20 September 1994|publisher=John Wiley & Sons|isbn=978-0-471-95052-3|pages=160–}}</ref><ref name="AnzenbacherZanger2012">{{cite book|author1=Pavel Anzenbacher|author2=Ulrich M. Zanger|title=Metabolism of Drugs and Other Xenobiotics|url=https://books.google.com/books?id=f-XHh17NfwgC&pg=PA302|date=23 February 2012|publisher=John Wiley & Sons|isbn=978-3-527-64632-6|pages=302–}}</ref> Other tertiary amine TCAs include [[amitriptyline]], [[clomipramine]], [[dosulepin]] (dothiepin), [[doxepin]], and [[trimipramine]].<ref name="Anthony2002">{{cite book|author=Patricia K. Anthony|title=Pharmacology Secrets|url=https://books.google.com/books?id=_QQsj3PAUrEC&pg=PA39|year=2002|publisher=Elsevier Health Sciences|isbn=1-56053-470-2|pages=39–}}</ref><ref name="CowenHarrison2012">{{cite book|author1=Philip Cowen|author2=Paul Harrison|author3=Tom Burns|title=Shorter Oxford Textbook of Psychiatry|url=https://books.google.com/books?id=Y1DtSGq-LnoC&pg=PA532|date=9 August 2012|publisher=OUP Oxford|isbn=978-0-19-162675-3|pages=532–}}</ref> The [[chemical name]] of imipramine is 3-(10,11-dihydro-5''H''-dibenzo[''b'',''f'']azepin-5-yl)-''N'',''N''-dimethylpropan-1-amine and its [[free base]] form has a [[chemical formula]] of C<sub>19</sub>H<sub>2</sub>N<sub>2</sub> with a [[molecular weight]] of 280.407&nbsp;g/mol.<ref name="Elks2014" /> The drug is used commercially mostly as the [[hydrochloride]] [[salt (chemistry)|salt]]; the [[embonate]] (pamoate) salt is used for intramuscular administration and the free base form is not used.<ref name="Elks2014" /><ref name="IndexNominum2000" /> The [[CAS Registry Number]] of the free base is 50-49-7, of the hydrochloride is 113-52-0, and of the embonate is 10075-24-8.<ref name="Elks2014" /><ref name="IndexNominum2000" />

==History==
Imipramine was discovered in 1951.<ref name=Wal2012>{{cite book|last1=Walker|first1=S. R.|title=Trends and Changes in Drug Research and Development|date=2012|publisher=Springer Science & Business Media|isbn=9789400926592|page=109|url=https://books.google.ca/books?id=FB_2CAAAQBAJ&pg=PA109|language=en}}</ref> It was initially developed as an [[antihistamine]] and [[major tranquilizer]] for use in patients with [[schizophrenia]]; its antidepressant effects were discovered serendipitously when moods of patients improved.<ref name="pmid6086881"/><ref name="MitchellTriggle2009">{{cite book|author1=E. Siobhan Mitchell|author2=D. J. Triggle|title=Antidepressants|url=https://books.google.com/books?id=Duy5_XAD-vgC&pg=PA15|year=2009|publisher=Infobase Publishing|isbn=978-1-4381-0192-7|pages=15–}}</ref>

In the late 1950s, imipramine was the first TCA to be developed (by [[Ciba-Geigy|Ciba]]). At the first international congress of neuro-pharmacology in Rome, September 1958 Dr Freyhan from the [[University of Pennsylvania]] discussed as one of the first clinicians the effects of imipramine in a group of 46 patients, most of them diagnosed as "depressive psychosis". The patients were selected for this study based on symptoms such as depressive apathy, kinetic retardation and feelings of hopelessness and despair. In 30% of all patients, he reported optimal results, and in around 20%, failure. The side effects noted were [[atropine]]-like, and most patients suffered from dizziness. Imipramine was first tried against psychotic disorders such as schizophrenia, but proved ineffective. As an antidepressant, it did well in clinical studies and it is known to work well in even the most severe cases of depression.<ref>{{Cite book|author=Healy, David|title=The Antidepressant Era|page =211|publisher= Harvard University Press|year= 1997}}</ref> It is not surprising, therefore, that imipramine may cause a high rate of manic and hypomanic reactions in hospitalized patients with pre-existing bipolar disorder, with one study showing that up to 25% of such patients maintained on Imipramine switched into mania or hypomania.<ref name="urlSpringerLink – Journal Article">{{cite journal| title = Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression| journal = European Archives of Psychiatry and Clinical Neuroscience| volume = 248| issue = 6| pages = 296–300| year = 1998| pmid = 9928908| doi = 10.1007/s004060050053| author1 = Bottlender| first1 = R| last2 = Rudolf| first2 = D| last3 = Strauss| first3 = A| last4 = Möller| first4 = H. J.}}</ref> Such powerful antidepressant properties have made it favorable in the treatment of [[treatment-resistant depression]].

Before the advent of [[selective serotonin reuptake inhibitor]]s (SSRIs), its sometimes intolerable side-effect profile was considered more tolerable. Therefore, it became extensively used as a standard antidepressant and later served as a prototypical drug for the development of the later-released TCAs. Today it is no longer used as commonly, but is sometimes still prescribed as a second-line treatment for treating major depression . It has also seen limited use in the treatment of [[migraine]]s, ADHD, and [[post-concussive syndrome]]. Imipramine has additional indications for the treatment of [[panic attacks]], [[chronic pain]], and [[Kleine-Levin syndrome]]. In pediatric patients, it is relatively frequently used to treat [[pavor nocturnus]] and [[nocturnal enuresis]].

==Society and culture==

===Generic names===
''Imipramine'' is the [[English language|English]] and [[French language|French]] [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|DCF|Dénomination Commune Française}}, while ''imipramine hydrochloride'' is its {{abbrlink|USAN|United States Adopted Name}}, {{abbrlink|USP|United States Pharmacopeia}}, {{abbrlink|BANM|British Approved Name}}, and {{abbrlink|JAN|Japanese Accepted Name}}.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA680|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=680–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA546|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=546–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA151|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=151–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/imipramine.html</ref> Its generic name in [[Spanish language|Spanish]] and [[Italian language|Italian]] and its {{abbrlink|DCIT|Denominazione Comune Italiana}} are ''imipramina'', in [[German language|German]] is ''imipramin'', and in [[Latin language|Latin]] is ''imipraminum''.<ref name="IndexNominum2000" /><ref name="Drugs.com" /> The embonate salt is known as ''imipramine pamoate''.<ref name="IndexNominum2000" /><ref name="Drugs.com" />

===Brand names===
Imipramine is marketed throughout the world mainly under the brand name '''Tofranil'''.<ref name="IndexNominum2000" /><ref name="Drugs.com" /> Imipramine pamoate is marketed under the brand name '''Tofranil-PM''' for [[intramuscular injection]].<ref name="IndexNominum2000" /><ref name="Drugs.com" /><ref name="Pies2007">{{cite book|author=Ronald W. Pies|title=Handbook of Essential Psychopharmacology|url=https://books.google.com/books?id=5XCKY-s6OVIC&pg=PA79|date=2 April 2007|publisher=American Psychiatric Pub|isbn=978-1-58562-660-1|pages=79–}}</ref>

==References==
{{Reflist|30em}}

==External links==
* [http://www.medicinenet.com/imipramine/article.htm Imipramine] – Medicinenet.com
* [http://www.neurotransmitter.net/drug_reference.html Neurotransmitter] – Neurotransmitter.net
* [http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=IXX Imipramine bound to proteins] in the [[Protein Data Bank|PDB]]

{{Antidepressants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Ion channel modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
{{Sigma receptor modulators}}
}}
{{Tricyclics}}

[[Category:Alpha blockers]]
[[Category:Amines]]
[[Category:D2 antagonists]]
[[Category:Dibenzazepines]]
[[Category:Glycine receptor antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Muscarinic antagonists]]
[[Category:Nicotinic antagonists]]
[[Category:Serotonin antagonists]]
[[Category:Serotonin-norepinephrine reuptake inhibitors]]
[[Category:Tricyclic antidepressants]]